HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.

AuthorsJunya Kuroda, Shinsuke Mizutani, Yuji Shimura, Saori Maegawa, Hisao Nagoshi, Yoshiaki Chinen, Shotaro Tatekawa, Taku Tsukamoto, Yoshimi Mizuno, Mio Yamamoto-Sugitani, Tsutomu Kobayashi, Yosuke Matsumoto, Shigeo Horiike, Masafumi Taniwaki
JournalAnnals of hematology (Ann Hematol) Vol. 94 Issue 4 Pg. 687-9 (Apr 2015) ISSN: 1432-0584 [Electronic] Germany
PMID25209844 (Publication Type: Case Reports, Letter)
Chemical References
  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Bortezomib
  • Dexamethasone
Topics
  • Administration, Intravenous
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (administration & dosage)
  • Boronic Acids (administration & dosage)
  • Bortezomib
  • Dexamethasone (administration & dosage)
  • Disease Progression
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Injections, Subcutaneous
  • Male
  • Multiple Myeloma (drug therapy, pathology)
  • Pyrazines (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: